Trial Profile
A Multicenter Trial Investigating the Duration of Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX Regimen for Patients With High Risk Stage II or Stage III Colon Cancer.
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 29 Jan 2021
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Oxaliplatin (Primary) ; Fluorouracil; Folinic acid
- Indications Adenocarcinoma; Colon cancer; Rectal cancer
- Focus Therapeutic Use
- Acronyms HORG-IDEA
- 13 Jan 2021 Results of the pooled analysis of the high-risk stage II disease individual patient data from the four studies within the IDEA collaboration published in the Journal of Clinical Oncology
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 20 Jan 2018 Results of a study assessing noninferiority of 3 month of oxaliplatin/fluoropyrimidines based adjuvant chemotherapy to the 6 month therapy presented at the 2018 Gastrointestinal Cancers Symposium